Brind.

Ligand Pharmaceuticals Commits $47M Funding and Royalty Rights to AvenCell Therapeutics

1 report, 1 independent Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ligand Pharmaceuticals announced a $47 million financing agreement with AvenCell Therapeutics, a private company developing CAR-T therapies. This commitment includes up to $6 million toward AvenCell’s Series C financing and up to $41 million for AvenCell’s drug development programs. The funding is staged, with the first tranche payable at closing and remaining tranches dependent on predetermined clinical milestones.

From insidermonkey.com

Why it matters

Some supportBrind's analysis of the reports

Ligand Pharmaceuticals operates a business model that generates income by funding third-party drug programs and acquiring royalty interests. This agreement expands that strategy by securing rights in AvenCell Therapeutics' pipeline, which includes programs currently in Phase 1a and Phase 1b trials.

From insidermonkey.com

Who's involved

  • Ligand PharmaceuticalsBiopharmaceutical company that funds third-party drug programs
  • NasdaqStock exchange where Ligand Pharmaceuticals trades its stock
  • Todd DavisChief Executive Officer of Ligand Pharmaceuticals
  • MerckCompany that partners with Ligand Pharmaceuticals to fund drug development

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped